Clinical Data's Cogenics Division and John Innes Centre Sign Genomics Collaboration Agreement

NEWTON, Mass--(BUSINESS WIRE)--Cogenics™, a division of Clinical Data, Inc. (NASDAQ:CLDA) announced today the completion of a multi-year agreement with the Norwich, UK-based John Innes Centre. Under the terms of the agreement, Cogenics will provide the John Innes Centre (JIC) with gene expression and other genomics services in a solutions-oriented approach that will help the John Innes Centre enhance its leading-edge plant science and microbiology research.

“Our partnership with Cogenics provides us with exciting opportunities to bring more advanced genomics technologies for plant and microbial research into the reach of the wider plant and microbial science community. We look forward to working with Cogenics on gene expression analysis and in other areas.”

JIC and Cogenics revealed the first result of their collaboration – a custom Brassica gene expression microarray – at the Plant and Animal Genome Conference in San Diego, California, on January 12, 2008. The custom Brassica microarray was developed in conjunction with the J. Craig Venter Institute, and allows researchers to interrogate 91,854 transcribed sequences across multiple Brassica species. Cogenics has opened up a new market opportunity by translating primary research data into a research tool of benefit to both commercial and academic sectors. Cogenics will continue to customize its services to help JIC achieve additional results of this type.

“Having access to high-quality, cost-effective technologies is a high priority for the John Innes Centre,” said Ian Bancroft, Project Leader in the JIC Crop Genetics Department and Head of the JIC Genome Laboratory. “Our partnership with Cogenics provides us with exciting opportunities to bring more advanced genomics technologies for plant and microbial research into the reach of the wider plant and microbial science community. We look forward to working with Cogenics on gene expression analysis and in other areas.”

“The Brassica microarray is an early example of what JIC and Cogenics are aiming to achieve through this partnership,” said Paul Tomlin, Director of European Operations for Cogenics. “The partnership goes beyond a purely transactional service model, highlighting the value of the unique, solutions-oriented approach that Cogenics delivers when matched with centers of excellence such as John Innes.”

For more information on Cogenics’ genomics services, please call 1-877-226-4364 or email sales@cogenics.com.

About Clinical Data, Inc.

Clinical Data, Inc. is unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare™. Its PGxHealth™ division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics™ division provides a broad range of molecular and pharmacogenomics services to pharmaceutical, biotechnology, and academic organizations in both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in pharmacogenomics to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company’s website at www.clda.com for more information.

About the John Innes Centre

John Innes Center is an independent, international centre of excellence in plant science and microbiology. Its mission is to carry out fundamental and strategic research, to train scientists and to make our findings available to society.

The scientific research at the Centre makes use of a wide range of disciplines in the biological and chemical sciences, including cell biology, biochemistry, chemistry, genetics, molecular biology, computational and mathematical biology.

The John Innes Centre is a registered charity (No. 223852) and a company limited by guarantee (registered in England No. 511709).

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company’s operations and results of significant acquisitions or divestitures made by major competitors; the Company’s ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data’s SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2007, and Quartely Report on Form 10-Q for the fiscal quarter ended September 30, 2007